dangers of compound semaglutide FDA alerts health care providers, compounders and patients dosing errors associated with compounded injectable products Demand Rising for 'Bootlegged' Weight-Loss

This suggests that weight loss is not the sole factor contributing to diabetes remission

Notably, at higher doses, weight loss appeared to be continuing at week 48 without a clear plateau

A study published in JAMA Ophthalmology in July 2024 found that individuals taking glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications may be at an increased risk for developing vision problems

Five to ten percent of patients discontinued the drug across doses, the company said, which was one of two late-stage trials the drug must pass before being submitted for federal approval

The $50 payment: Does not count toward your Medicare Part D deductible

Everything below is reported from per-compound clinical literature and self-organized community protocols